StreetAlpha.app
Home › Stocks › RXST

RxSight, Inc. (RXST)

Healthcare
$4.47
▼ −3.04%
LAST CLOSE · NOV 20

RxSight makes a premium cataract lens system that lets eye surgeons adjust a patient's vision after surgery. It last closed at $4.47 on Nov 20, down 3.04% on the day. The next earnings report for RXST is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, RXST reported EPS of -$0.39 on revenue of $24.6M, with revenue down 19.0% from a year ago. Over its last 8 reports the stock moved an average of 6.0% the session after earnings. Over the last 12 months RXST insiders bought $0 of stock on the open market and sold $118K, according to SEC Form 4 filings.

AI Auto Pilots
Is RXST in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RXST.

Key Stats

Last 12 months
Results
Revenue
$121.8M
−14.3% vs a year ago
Net income
−$53.4M
−43.8% margin
EPS (diluted)
−$1.29
Free cash flow
$18.6M
15.3% margin
Valuation
Market cap
$187.4M
41.9M shares
P/E
–
No P/E while losing money
Price to sales
1.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$66.7M
At Sep 30
Shareholder equity
$254.9M
Shares outstanding
41.9M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $22.6M$22.6MFY2021FY2022: $49.0M$49.0MFY2022FY2023: $89.1M$89.1MFY2023FY2024: $139.9M$139.9MFY2024FY2025: $134.5M$134.5MFY2025

From RXST's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
-$0.39
Quarter ended Sep 2026
Year ago EPS
-$0.24
Same quarter last year
Revenue
$24.6M
−19.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.15Dec '24Mar 2025: -$0.20Mar '25Jun 2025: -$0.29Jun '25Sep 2025: -$0.24Sep '25Dec 2025: -$0.22Dec '25Mar 2026: -$0.38Mar '26Jun 2026: -$0.29Jun '26Sep 2026: -$0.39Sep '26Latest -$0.39
Revenue by quarter
Dec 2024: $40.2MDec '24Mar 2025: $37.9MMar '25Jun 2025: $33.6MJun '25Sep 2025: $30.3MSep '25Dec 2025: $32.6MDec '25Mar 2026: $30.9MMar '26Jun 2026: $33.7MJun '26Sep 2026: $24.6MSep '26Latest $24.6M
How RXST moved after its last 8 reports
Average move the session after a report ±6.0%
Nov 3, 2026After the close+8.7%
Aug 5, 2026After the close−3.3%
Jul 6, 2026After the close+0.4%
May 6, 2026After the close−14.4%
Feb 25, 2026After the close−10.1%
Jan 12, 2026After the close+0.2%
Nov 5, 2025After the close+3.2%
Aug 7, 2025After the close−7.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RXSTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RXST
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RXST

Technical Analysis

RXST · as of the Nov 20 close · updated each morning
Downtrend

The stock is 10% below its 20 day and 10% below its 50 day average. It is 35% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the swing low (Oct 14) at $4.40, and the nearest resistance the Pivot at $4.56.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 8.2%/day
Key levels
$13.2252 week high+195.7%
$6.05200 day average+35.3%
$5.49100 day average+22.8%
$4.98Swing high (Oct 12)+11.4%
$4.9020 day average+9.6%
$4.9050 day average+9.6%
$4.66Pivot R1+4.3%
$4.56Pivot+2.0%
$4.47Last close
$4.40Swing low (Oct 14)−1.6%
$4.36Pivot S1−2.5%
$4.1152 week low−8.1%
Indicators
RSI (14)40.51Middle of its rangeNeutral
MACD-0.04Below its signal lineBearish
Stochastic38.6Middle of its rangeNeutral
ADX (14)20.5Weak trend
Williams %R-76.3Oversold below −80, overbought above −20Neutral
CCI (20)-137.5Oversold below −100, overbought above 100Oversold
Rate of change−1.5%Change over 10 sessionsBearish
ATR (14)$0.37Typical daily range, 8.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RXST

What happened before

See how RXST did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RXST usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RXST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RXSTHow many large options trades hit RXST, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

RXST Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●74 buying vs 78 selling
  • ▼Held by funds -12.5 pts
  • ▲Funds holding +5
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding156151+3.3%
In funds' top 10110.0%
Held by funds86.3%98.8%−12.5 pts
New / increased25 / 4925 / 72−23.7%
Reduced / sold out58 / 2035 / 36+9.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RXST institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RXST Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$118K4 sales · 4 insiders
2026-09 sold $118KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 2Eric WeinbergSee remarksSale2,041$6.96$14K
Sep 2Ilya GoldshlegerCOOSale2,041$6.96$14K
Sep 2Mark WilterdingCFOSale7,765$6.96$54K
Sep 2Ronald M Kurtz MDChief Medical OfficerSale5,100$6.96$35K
Mar 12, 2025Tamara FountainDirectorSale plan7,000$25.71$180K
Jan 22, 2025Shweta ManiarDirectorSale plan3,519$30.87$109K
Every insider buy and sale for RXST over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RXST insider trades →

From SEC Form 4 filings by RXST's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RXST is in one of them and how their past RXST trades turned out.

RXST in the AI portfolios
Loading…

RXST News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RXST in an article yet. Here's the latest on the wider market.

RXST in the news

About RxSight

RxSight is a medical technology company based in Aliso Viejo, California. It makes a premium cataract lens system that lets eye surgeons adjust a patient's vision after surgery. The system includes an implantable lens and a light device that uses ultraviolet light to change the lens's focusing power. Its customers are eye surgeons and ophthalmology practices, mainly in the United States, and its end users are patients undergoing cataract surgery.

Headquarters
Aliso Viejo, CA